ATON Partners

Investment decisions are made by co-founders Patrick Sullivan and Daniel Levangie, who share a decades-long track record operating and investing in medical-device companies. Both have led companies from concept-stage technology development through to profitable exits, most notably during their joint tenure at Cytyc Corporation and with the Bloodhound hematology platform.

ATON sources opportunities through the co-founders’ individual networks built across twenty-plus years of medical-device and diagnostics operating experience. The firm’s hybrid model — offering management advisory services to early-stage companies — creates a proprietary pipeline where consulting engagements can convert into direct investment opportunities.

ATON Partners is structured as a private equity firm, not a family office. The firm deploys the principals’ capital alongside providing management advisory services, but does not operate as a fiduciary for any single family's assets or manage third-party limited-partner capital according to publicly available information.

The firm focuses exclusively on direct investments, typically taking active advisory or operating roles within its portfolio companies. ATON’s known public record shows equity positions in companies where the principals also drive strategic decisions, rather than making fund-of-fund commitments.

ATON targets early-stage companies, placing capital at the concept and early-commercialization phases of development before clinical or scale validation. The approach reflects the co-founders’ operating playbook of guiding immature technologies through regulatory approval and market adoption, as they did with Cytyc’s ThinPrep Pap Test and with Roche-acquired Bloodhound.